Oncology

In the United States, where 1 in 680 people between 20 and 50 years old are survivors of childhood cancer, the impact of long-term health consequences is a cause for concern, and even more so because this population is increasing.

This week CMS released their third round of annual data, the value-based topics of the American Society of Clinical Oncology gained new ground, and The American Journal of Managed Care will travel to their 75th session of the American Diabetes Association in Boston.

Data represented May 18, 2015, at the American Urological Association annual meeting in New Orleans, certainly grabbed headlines.

The report found a 6.5% increase in the compound annual growth rate during the 5-year period leading up to 2014.

BMS has submitted phase 3 results from the CheckMate-066 trial, comparing nivolumab with dacarbazine in treatment-naïve advanced melanoma patients.

Evidence-Based Oncology's editor in chief introduces the special issue on cardio-oncology.

A US appeals court has blocked Novartis from selling the first biosimilar to be approved in the United States.

Will Sandoz' biosimilar, first ever in the US, ever see the light of day?

While the 21st Century Cures Act that was recently approved is full of promise for healthcare innovation, experts warn against some of the Act's provisions.

A session at the 64th Annual Scientific Session of the American College of Cardiology evaluated the cardiotoxic outcomes of treatment in cancer survivors.

On the first day of the NCCN 20th Annual Conference in Hollywood, Florida, March 12-14, 2015, panelists took a look back at the last 20 years of the NCCN and why it succeeded when others had failed before.

Participants on the second day of the National Comprehensive Cancer Network 20th Annual Conference in Hollywood, Florida, March 12-14, 2015, spent a long time defining value in cancer care and how it can be incorporated into healthcare decision making.

During the session "Principles of Immunotherapy" at the National Comprehensive Cancer Network 20th Annual Conference in Hollywood, Florida, Anthony J. Olszanski, RPh, MD, from the Fox Chase Cancer Center, described the complex interplay between the immune system and cancer.

Biomarker-directed regimens in cancer not only ensure treatment for the right patient population, it also makes economic sense, especially in today's climate of high-cost specialty medications like the novel immunooncology agents, nivolumab and pembrolizumab.

Anju Nohria, MD, assistant professor, Harvard Medical School, spoke to Evidence-Based Oncology about some of the challenges clinicians face with monitoring cardiovascular risks in cancer patients.

A Cardio-Oncology Working Group formed by the ACC conducted a nationwide survey focused on cardio-oncology services, gathering opinions from cardiovascular division chiefs and fellowship training directors. This helped identify important challenges, including the need for broader educational opportunities and training.

The American Journal of Managed Care convened experts in health policy, from health plans, and from community oncology, to discuss OCM and other issues in oncology care during the Oncology Stakeholders Summit, Spring 2015 Peer Exchange.

To discuss patient-reported outcomes and their importance in patient-centered care, The American Journal of Managed Care convened a panel of healthcare experts to participate in the Oncology Stakeholders Summit, Spring 2015 Peer Exchange.

Luis A. Diaz, Jr, MD, associate professor of oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discovered that patients with high mutational burden with mismatched repair responded well to checkpoint inhibition of PD1.